Polifeprosan 20, 3.85% Carmustine Slow-Release Wafer in Malignant Glioma: Evidence for Role in Era of Standard Adjuvant Temozolomide

Core Evidence - New Zealand
doi 10.2147/ce.s23244
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Polifeprosan 20, 3.85% Carmustine Slow Release Wafer in Malignant Glioma: Patient Selection and Perspectives on a Low-Burden Therapy

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2016English

Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2010English

The Strategy for Enhancing Temozolomide Against Malignant Glioma

Frontiers in Oncology
Cancer ResearchOncology
2012English

Impact of Temozolomide on Immune Response During Malignant Glioma Chemotherapy

Clinical and Developmental Immunology
2012English

Adjuvant Chemotherapy for Adults With Malignant Glioma: A Systematic Review

Canadian Journal of Neurological Sciences
MedicineNeurology
2007English

Immune Response in Malignant Glioma

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2010English

MicroRNA-93 Promotes the Malignant Phenotypes of Human Glioma Cells and Induces Their Chemoresistance to Temozolomide

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2016English

Phase 1b/2a Study of Galunisertib, a Small Molecule Inhibitor of Transforming Growth Factor-Beta Receptor I, in Combination With Standard Temozolomide-Based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Investigational New Drugs
OncologyPharmacology
2020English

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma

World Journal of Oncology
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy